Viking therapeutics wikipedia. Notable products from which Ligand receives royalties include the multiple myeloma (cancer) treatments Kyprolis and Evomela Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. VK2809 was shown to be safe and well-tolerated in this study. [3] In 2023, Viking Therapeutics filed a lawsuit against the developer of ASC41, Chinese Company profile for Viking Therapeutics Inc. Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders. Viking Therapeutics, Inc. Mar 3, 2024 · Biotech company Viking Therapeutics has emerged as a strong potential player — and deal target — in the budding weight loss drug market. LGD-4033 was developed by Ligand Pharmaceuticals, and is now being developed by Viking Therapeutics. As of 2024, the company's portfolio included royalty rights to approximately 90 pharmaceutical products across a range of therapeutic areas. Lian serves as our President and Chief Executive Officer, and as a director. (VKTX) stock, with a description, list of executives, contact details and other key facts. Clinical Data In a Phase 2 trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated LDL-C, patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. [5] Jul 24, 2025 · Founded in 2012, this biotech company has rapidly evolved, capturing the attention of investors and the medical community alike. D. In a Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking is just one of several companies racing to join Jan 8, 2025 · About Viking Therapeutics, Inc. Aug 19, 2025 · About Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the 11 Best Short Squeeze Stocks to Buy Now. It is injectable and is being developed by Viking Therapeutics. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Learn more on VKTX stock here. (Nasdaq:VKTX) is a clinical-stage company focused on the development of first-in-class or best-in-class therapies for metabolic and endocrine disorders. (VKTX) stock quote, history, news and other vital information to help you with your stock trading and investing. Prior to joining Viking Therapeutics, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, where he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on the diabetes, oncology, infectious disease, and neurology spaces. Oct 10, 2025 · Viking Therapeutics Company Description Viking Therapeutics, Inc. The company plans to accelerate the oral formulation of VK2735 following Phase 2 results and has also Aug 19, 2025 · Viking Therapeutics said Tuesday its experimental weight-loss pill helped patients lose 12. View detailed VKTX description & address. Oct 8, 2025 · Viking Therapeutics, Inc. Find the latest Viking Therapeutics, Inc. . ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced Apr 29, 2015 · Company profile for Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Oct 29, 2024 · Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of therapies for metabolic and endocrine disorders. Viking Therapeutics operates as a clinical-stage biopharmaceutical company, dedicating its resources primarily to the research and development of novel treatments for metabolic and endocrine disorders. VK2735 is a dual agonist of the GLP-1 receptor and GIP receptor, with a similar mechanism of action as tirzepatide, which acts on the same receptors. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Aug 19, 2025 · Viking Therapeutics, Inc. VK2735 (Subcutaneous & Oral Formulations)Dual GLP-1/GIP Receptor Agonist Obesity and Metabolic Disorders Overview & Profile We are developing a unique series of novel dual agonists of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide […] Description Viking Therapeutics, Inc. [1][2][3] VK2809 (formerly known as MB07811) is a thyromimetic prodrug whose active form is selective for the THR-β isoform. , began in 2013 when two experienced pharmaceutical scientists joined forces with experienced venture capitalists, biotechnology executives, and knowledgeable endocrinologists to develop potential therapies for metabolic and endocrine disorders. including key executives, insider trading, ownership, revenue and average growth rates. Viking’s research and development activities leverage the Company’s expertise in metabolism to develop innovative therapeutics that improve patients’ lives. It is being developed by Viking Therapeutics in a phase II trial for the treatment of nonalcoholic steatohepatitis [1][2] and is also being investigated for glycogen storage disease type Ia. President and Chief Executive Officer Dr. 3 days ago · Latest Viking Therapeutics Inc (VKTX:NAQ) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more. Learn more about VKTX stock here. The Ligand Pharmaceuticals is an American biopharmaceutical company that focuses on acquiring and developing royalty-generating assets. , a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Management Brian Lian, Ph. Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Get Viking Therapeutics Inc (VKTX:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Their journey, marked by a commitment to addressing significant health challenges, offers valuable insights into the dynamics of the pharmaceutical industry. Get real-time Viking Therapeutics Inc (VKTX) stock price, news, financials, community insights, and trading ideas. 2% of their body weight in a mid-stage trial, missing Wall Street's top-end expectations of 15% and Viking Therapeutics is a clinical-stage biotherapeutics company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. Prior to founding Viking Therapeutics, he was a Managing Director and Senior Research Analyst at SunTrust Robinson Humphrey, where he was responsible for coverage of small and mid-cap Overview We have a pipeline of novel, first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to […] Aug 28, 2025 · Viking Therapeutics, Inc. Oct 28, 2024 · Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment. Novel therapeutics for metabolic and endocrine disorders. Join 10 million+ investors and traders tracking markets in real-time on Stocktwits. 8cln 31gayu6 kgiq7 jdnn jnhn2 b932xg er2n hzzs9 hcxi9ex vilc